WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue ...
WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B ...
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist ...
(MENAFN- EIN Presswire) EINPresswire/ -- "The hepatitis B virus (HBV) capsid inhibitors market is gaining significant attention as new treatment options emerge for managing chronic HBV infection. With ...
Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 WARMINSTER, ...
Arbutus Biopharma is officially canning its RNA-destabilizing hepatitis B program due to safety concerns found in preclinical studies carried out in two species. The move comes four months after the ...
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on ...
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results